Merck's revenues are driven by cancer med Keytruda, which faces patent expiry by 2028. See why I rate MRK stock a hold.

We recently published a list of Jim Cramer Focused On These 9 Stocks Recently. In this article, we are going to take a look ...

Merck (NYSE:MRK) has recently achieved a significant milestone with the European Commission's approval of its pneumococcal vaccine CAPVAXIVE®, boosting its portfolio in the vaccines market. Despite ...

Merck and Bristol-Myers Squibb are key players in cancer treatment. Find out why MRK and BMY stocks have different prospects ...

NEW YORK, NY / ACCESS Newswire / March 25, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Merck & Co., Inc. (NYSE:MRK) between February 3, 2022 and ...

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Merck & Co., Inc. ("Merck" or the "Company") (NYSE: MRK) and reminds investors of the April 14, ...

Strong positive interim data from an earlier Phase 3 trial has led to early cessation of Merck’s pulmonary arterial ...

We recently published a list of 15 Best Defensive Stocks Amid Market Volatility In this article, we are going to take a look ...

We recently published a list of Jim Cramer Recently Put These 10 Stocks Under Spotlight. In this article, we are going to ...

CASE DETAILS: According to the complaint, defendants provided investors with material information concerning Merck's expected revenue of $11 billion from sales of Gardasil by 2030. Defendants' ...

In addition to this, Moody’s upgraded Merck & Co., Inc.’s senior unsecured revolving credit facility to Aa3 from A1, and the senior unsecured shelf ratings of both Merck & Co., Inc. and MSD ...